Thera-SAbDab

BEVACIZUMAB

>   Structural Summary
TherapeuticBevacizumab
TargetVEGFA
Heavy ChainEVQLVESGGGLVQPGGSLRLSCAASGYTFTNYGMNWVRQAPGKGLEWVGWINTYTGEPTYAADFKRRFTFSLDTSKSTAYLQMNSLRAEDTAVYYCAKYPHYYGSSHWYFDVWGQGTLVTVSS
Light ChainDIQMTQSPSSLSASVGDRVTITCSASQDISNYLNWYQQKPGKAPKVLIYFTSSLHSGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQYSTVPWTFGQGTKVEIK
100% seqID Fv Structure1bj1 [Fvs: HL, KJ]
99% seqID Fv StructureNone
95-98% seqID Fv Structure1cz8 [Fvs: HL, YX], 6bft [Fvs: AB, HL]
>   Alignments

Non-identical sequences have been numbered using the Chothia scheme and aligned to Bevacizumab.
CDR positions are indicated in blue. Mismatching positions are highlighted in orange.

Sequence identity: 98.26%

Heavy chain

Position 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 52A 53 54 55 56 57 58 59 60 61 62 63 64 65 66 67 68 69 70 71 72 73 74 75 76 77 78 79 80 81 82 82A 82B 82C 83 84 85 86 87 88 89 90 91 92 93 94 95 96 97 98 99 100 100A 100B 100C 100D 100E 100F 101 102 103 104 105 106 107 108 109 110 111 112 113
bevacizumab E V Q L V E S G G G L V Q P G G S L R L S C A A S G Y T F T N Y G M N W V R Q A P G K G L E W V G W I N T Y T G E P T Y A A D F K R R F T F S L D T S K S T A Y L Q M N S L R A E D T A V Y Y C A K Y P H Y Y G S S H W Y F D V W G Q G T L V T V S S
6bft E V Q L V E S G G G L V Q P G G S L R L S C A A S G Y D F D N Y G M N W V R Q A P G K G L E W V G W I N T Y T G E P T Y A A D F K R R F T F S L D T S K S T A Y L Q M N S L R A E D T A V Y Y C A K Y P H Y Y G S S H W Y F D V W G Q G T L V T V S S

Light chain

Position 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60 61 62 63 64 65 66 67 68 69 70 71 72 73 74 75 76 77 78 79 80 81 82 83 84 85 86 87 88 89 90 91 92 93 94 95 96 97 98 99 100 101 102 103 104 105 106 107
bevacizumab D I Q M T Q S P S S L S A S V G D R V T I T C S A S Q D I S N Y L N W Y Q Q K P G K A P K V L I Y F T S S L H S G V P S R F S G S G S G T D F T L T I S S L Q P E D F A T Y Y C Q Q Y S T V P W T F G Q G T K V E I K
6bft D I Q M T Q S P S S L S A S V G D R V T I T C S A S Q D I S N Y L N W Y Q Q K P G K A P K V L I Y F T D D L H S G V P S R F S G S G S G T D F T L T I S S L Q P E D F A T Y Y C Q Q Y S T V P W T F G Q G T K V E I K
Sequence identity: 97.83%

Heavy chain

Position 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 52A 53 54 55 56 57 58 59 60 61 62 63 64 65 66 67 68 69 70 71 72 73 74 75 76 77 78 79 80 81 82 82A 82B 82C 83 84 85 86 87 88 89 90 91 92 93 94 95 96 97 98 99 100 100A 100B 100C 100D 100E 100F 101 102 103 104 105 106 107 108 109 110 111 112 113
bevacizumab E V Q L V E S G G G L V Q P G G S L R L S C A A S G Y T F T N Y G M N W V R Q A P G K G L E W V G W I N T Y T G E P T Y A A D F K R R F T F S L D T S K S T A Y L Q M N S L R A E D T A V Y Y C A K Y P H Y Y G S S H W Y F D V W G Q G T L V T V S S
1cz8 E V Q L V E S G G G L V Q P G G S L R L S C A A S G Y D F T H Y G M N W V R Q A P G K G L E W V G W I N T Y T G E P T Y A A D F K R R F T F S L D T S K S T A Y L Q M N S L R A E D T A V Y Y C A K Y P Y Y Y G T S H W Y F D V W G Q G T L V T V S S

Light chain

Position 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60 61 62 63 64 65 66 67 68 69 70 71 72 73 74 75 76 77 78 79 80 81 82 83 84 85 86 87 88 89 90 91 92 93 94 95 96 97 98 99 100 101 102 103 104 105 106 107
bevacizumab D I Q M T Q S P S S L S A S V G D R V T I T C S A S Q D I S N Y L N W Y Q Q K P G K A P K V L I Y F T S S L H S G V P S R F S G S G S G T D F T L T I S S L Q P E D F A T Y Y C Q Q Y S T V P W T F G Q G T K V E I K
1cz8 D I Q L T Q S P S S L S A S V G D R V T I T C S A S Q D I S N Y L N W Y Q Q K P G K A P K V L I Y F T S S L H S G V P S R F S G S G S G T D F T L T I S S L Q P E D F A T Y Y C Q Q Y S T V P W T F G Q G T K V E I K
>   Metadata
FormatWhole mAb
IsotypeG1
Highest Clinical Trial (June '19)Approved
Estimated Status (June '19)Active
Recorded Developmental Technologyna
INN Year Proposed2000
INN Year Recommended2001
Companies InvolvedAll Ireland Cooperative Oncology Research Group, ARCAGY/GINECO Group, Austrian Breast & Colorectal Cancer Study Group, Bayer, Beth Israel Deaconess Medical Center, Breast Cancer Research Foundation, Brigham and Women's Hospital, Bristol-Myers Squibb, Cancer and Leukemia Group B, Cancer Research UK, Chugai Pharmaceutical, Cincinnati Children's Hospital Medical Center, Dana-Farber Cancer Institute, Duke University, European Organisation for Research and Treatment of Cancer, European Thoracic Oncology Platform, Genentech, Hackensack University Medical Center, Hoosier Cancer Research Network, Indiana University School of Medicine, Japan Breast Cancer Research Group, M. D. Anderson Cancer Center, Massachusetts General Hospital, Medical University of South Carolina, Melanoma Research Foundation Breakthrough Consortium, Memorial Sloan-Kettering Cancer Center, National Cancer Institute (USA), National Comprehensive Cancer Network, NCIC Clinical Trials Group, North Central Cancer Treatment Group, NSABP Foundation, Ohio State University Medical Center, Peter MacCallum Cancer Centre, Roche, Royal Marsden NHS Foundation Trust, Sanofi, Sarcoma Alliance for Research through Collaboration, SCRI Development Innovations, South Eastern European Research Oncology Group, Spanish Cooperative Group for Digestive Tumour Therapy, Spanish Lung Cancer Group, Stanford University School of Medicine, SWOG, The Catalan Institute of Oncology, UNICANCER, University College London, University of Alabama at Birmingham, University of Arkansas System, University of California Davis, University of Iowa, University of Oklahoma, University of Tennessee, University of Texas M. D. Anderson Cancer Center, US Oncology Research, West German Study Group, Xijing Hospital
Conditions ApprovedBreast cancer, Cervical cancer, Colorectal cancer, Glioblastoma, Glioma, Non-small cell lung cancer, Ovarian cancer, Renal cell carcinoma, Fallopian tube cancer, Peritoneal cancer
Conditions ActiveHead and neck cancer, Biliary cancer, Brain metastases, Endometrial cancer, Ewing's sarcoma, Gynaecological cancer, Hodgkin's disease, Intestinal cancer, Liver cancer, Liver metastases, Malignant melanoma, Meningioma, Multiple myeloma, Neuroblastoma, Neurofibromatoses, Rectal cancer, Soft tissue sarcoma, Solid tumours, Urogenital cancer, Neoplastic meningitis, Sarcoma
Conditions DiscontinuedCarcinoid tumour, Chronic lymphocytic leukaemia, Diffuse large B cell lymphoma, Eye disorders, Gastric cancer, Gastrointestinal stromal tumours, Mesothelioma, Oesophageal cancer, Pancreatic cancer, Prostate cancer, Small cell lung cancer
Notes

SAbDab paper: Dunbar, J., Krawczyk, K. et al (2014). Nucleic Acids Res. 42. D1140-D1146 [link]

Thera-SAbDab paper: Raybould, M.I.J., Marks, C. et al (2019). Nucleic Acids Res. gkz827 [link]